Cancer Models Forum

Posted by Repositive, June 2020

Preclinical cancer model spotlight: June edition

As part of our commitment to the preclinical oncology community, we want to go one step further to support pharma and biotech researchers during this difficult time. With many scientists around the world starting to return to the laboratory over the coming weeks, we want to help you effectively plan and kick-off any delayed or rescheduled preclinical studies.

In our new blog series, we’ll be highlighting a selection of popular, interesting and uncommon models available from our specialist CRO partners, which might be of interest for your upcoming studies. And we’re providing insight into the molecular, patient, drug response, histology and growth curve data available for each – information that is currently only available to the enterprise users of our Cancer Models Platform.

1. Metastatic breast invasive ductal adenocarcinoma PDX model with ERBB2 amplification

First up in our model spotlight is a metastatic breast adenocarcinoma PDX model from one of the world-leading CRO partners.

  • Patient information This breast adenocarcinoma model was created using a tumour sample from a 48-year old female patient whose tumour had metastasised to the skin.

  • Molecular and growth rate characteristics The model is characterised by a 7.6-day tumour volume doubling time and ERBB2 gene amplification, which can be validated by whole-exome sequencing, RNA-seq and microarray data.

  • Histology analysis Here is a closer look at the histology of this PDX model under both 5X and 40X magnification, which confirms that the tumour is of invasive ductal adenocarcinoma subtype.

Breast cancer histology image 5X

Breast cancer model histology 40X

Want more information or access to this model? Request more information or get in touch with our experts via our Cancer Models Platform.

Learn more CTA button

2. Primary colorectal carcinoma organoid with mutations in key driver genes, APC and BRAF

With the ever-growing interest in the use of organoids for enhancing cancer drug discovery and development, we couldn’t not include this primary colorectal carcinoma organoid model from one of our dedicated organoid providers.

  • Mutation profile The organoid was derived from malignant colorectal carcinoma tumour samples and harbours mutations in key driver genes including, APC and BRAF, which have been validated with whole-exome sequencing. The model also has mutations in a number of other important genes, such as SMAD2, ARID2 and CTNNB1, while SMAD4, NRAS, TP53 and POLE amongst others are wildtype.

  • Intronic modifiers up/downstream of genes In addition to the mutation profile of this colorectal cancer organoid, intronic modifiers with the potential to alter gene regulation can be found up/downstream of the following genes: KRAS, PIK3CA, ARID1A, AXIN2, ERBB3 and MSH3.

  • Drug treatment data and histology analysis This patient-derived colorectal carcinoma organoid has been validated in-house by our CRO partner for its response to a number of pharmacological agents. Paraffin-embedded sections can also be provided for histology analysis if required.

Want more information or access to this model? Request more information or get in touch with our experts via our Cancer Models Platform.

Learn more CTA button

3. Metastatic Non-Small Cell Lung Cancer PDX model with EGFR mutations

Last up in our June spotlight is this metastatic Non-Small Cell Lung Cancer (NSCLC) PDX model with various mutations in the EGFR gene.

  • Patient information This PDX model was created from a tumour sample collected from a 58-year-old Caucasian male whose NSCLC (subtype: adenocarcinoma) had metastasised to the lymph nodes.

  • Molecular and growth rate characteristics The model is characterised by various mutations in the EGFR gene, with whole-exome sequencing, RNA-seq and microarray data available to validate each. The tumour volume doubling time is 5.4 days.

  • Model drug treatment response The effect of administrating paclitaxel or cetuximab on the model's tumour growth rate has also been investigated, with paclitaxel having the greatest effect on slowing the growth rate of the tumour.

Lung cancer growth rate drug response curve

  • Histology analysis Here is a closer look at the histology of this PDX model under both 5X and 40X magnification, which confirms that the tumour is of adenocarcinoma subtype.

Lung cancer histology analysis 5X

Lung cancer model histology analysis 40X

Want more information or access to this model? Request more information or get in touch with our experts via our Cancer Models Platform.

Learn more CTA button

Need this level of molecular, drug treatment, histology and growth curve data for all your model searches?

Get in touch with our Business Development Team at BizDev@repositive.io to learn more about our enterprise subscription packages for our Cancer Models Platform, which can be tailored and customised to your organisation’s needs and requirements.

Image credit: Alinenok sourced from Unsplash

Model data, growth curves and histology images shared with permission from our CRO partners